Discovery of
Acinetobacter
/ drug effects
Animals
Anti-Bacterial Agents
/ chemistry
Binding Sites
Carbapenems
/ pharmacology
Drug Evaluation, Preclinical
Drug Resistance, Bacterial
/ drug effects
Enterobacteriaceae
/ drug effects
Half-Life
Mice
Microbial Sensitivity Tests
Molecular Docking Simulation
Octanes
/ chemistry
Stereoisomerism
Structure-Activity Relationship
beta-Lactamase Inhibitors
/ chemistry
beta-Lactamases
/ chemistry
Journal
Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531
Informations de publication
Date de publication:
24 12 2020
24 12 2020
Historique:
pubmed:
12
12
2020
medline:
3
2
2021
entrez:
11
12
2020
Statut:
ppublish
Résumé
The diazabicyclooctanes (DBOs) are a class of serine β-lactamase (SBL) inhibitors that use a strained urea moiety as the warhead to react with the active serine residue in the active site of SBLs. The first in-class drug, avibactam, as well as several other recently approved DBOs (e.g., relebactam) or those in clinical development (e.g., nacubactam and zidebactam) potentiate activity of β-lactam antibiotics, to various extents, against carbapenem-resistant Enterobacterales (CRE) carrying class A, C, and D SBLs; however, none of these are able to rescue the activity of β-lactam antibiotics against carbapenem-resistant
Identifiants
pubmed: 33306385
doi: 10.1021/acs.jmedchem.0c01535
doi:
Substances chimiques
Anti-Bacterial Agents
0
Carbapenems
0
Octanes
0
beta-Lactamase Inhibitors
0
beta-Lactamases
EC 3.5.2.6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM